EU CHMP Adopts Positive Opinion Recommending Approval Of KEYTRUDA, Merck’s Anti-PD-1 Therapy, In Combination With Padcev As Neoadjuvant Treatment For Adults With Resectable Muscle-Invasive Bladder Cancer
Key takeaways
- EU regulators are poised to approve the first PD‑1 inhibitor plus antibody‑drug conjugate combo for bladder cancer, based on strong Phase 3 data.
- Phase 3 KEYNOTE‑B15 trial
- Event‑free survival
- Overall survival
What happened
The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval of Merck’s KEYTRUDA (pembrolizumab) in combination with Padcev (enfortumab vedotin‑ejfv) for neoadjuvant and adjuvant treatment of adults with resectable muscle‑invasive bladder cancer.
Why it matters
If approved, the combination would become the first and only PD‑1 inhibitor plus antibody‑drug conjugate regimen for MIBC patients in the EU, regardless of cisplatin eligibility, potentially expanding treatment options and improving outcomes.
Short-term and longer-term
Short-term. Short‑term traders should watch for the European Commission’s decision in Q4 2026, as approval could lift MRK shares and increase demand for Padcev.
Longer-term. Long‑term investors should note that the approval would broaden Merck’s oncology portfolio and potentially increase revenue streams from bladder cancer treatment.